MIR25 (MicroRNA 25)

In summary, we found that H3K27 acetylation-induced lncRNA-DAPK1-IT1 promotes oxidative stress damage caused by I/R through the miR-25-3p/HMGB1 axis. These findings help to improve our understanding of ischemic stroke and provide new therapeutic avenues.

Liquid biopsy holds strong potential for transforming bone tumor care. Its clinical adoption depends on further validation through standardized methods and large-scale studies.

These articles have been retracted. The Publisher apologizes for any inconvenience this may cause.

Furthermore, survival analysis revealed that miR-93-5p (HR = 0.72, p = 0.0246), HCC stage (HR = 2.43, p = 0.0000113), TCF4 (HR = 0.66, p = 0.0106), DNAJB4 (HR = 1.29, p = 0.0214), MCC (HR = 1.35, p = 0.0268), and CYB5A (HR = 0.77, p = 0.0423) affect overall survival (OS). Finally, a combined prognostic model for the miRNA cluster and its target genes via the random forest approach revealed that the miR-106b/25 cluster and its interactome are significantly associated with OS (p < 0.0001), thereby providing a comprehensive understanding of the cluster and its targets in the development and progression of HCC and its use as a potential marker for HCC.

Curcumin effectively inhibits EMT by inactivating the TGF-β1/Smads pathway through regulating XIST/miR-25-3p, and thereby alleviating the progression ofOSF. The study results further reveal the mechanisms underlying the function of curcumin, and may provide novel targets and ideas for OSF therapy.

The modulation of miR-25-3p impacts the behavior of T24 bladder cancer cells and may indicate its role in disease progression. Our results underscore the potential of miR-25-3p as a prognostic biomarker and support further studies considering its therapeutic relevance in managing high-grade and muscle-invasive bladder cancer.

Inhibition of the miR-106b-25 cluster increases caspase-3/7 activity. These findings demonstrate that both MCM7 and the miR-106b-25 cluster contribute to renal cancer progression.

Additionally, activated HSCs secreted vascular endothelial growth factor (VEGF), further driving pancreatic cancer metastasis and progression. These results suggest that miR-25-3p could serve as a novel biomarker for pancreatic cancer progression and a potential therapeutic target to improve patient outcomes.

This study demonstrates the potential of circulating miRNAs as valuable biomarkers for pediatric glioma detection and monitoring. Five examined circulating miRNAs were differentially expressed in pediatric glioma patients compared to controls. These miRNAs were correlated with glioma and could distinguish healthy from gliomas patients. Statistical analysis suggested these miRNAs may also distinguish between various glioma subtypes. Inhibition of the most promising circulating miRNA, miR-182-5p, decreased migration ability and invasiveness of pediatric high-grade glioma IV cells. In the future, the miRNAs studied could have applications as biomarkers for clinical management and treatment targets.

Moreover, along with the TCGA-validated hydroxyacyl-CoA dehydrogenase (HADH), the epithelial splicing regulatory protein-2 (ESRP2) and dihydrolipoamide branched chain transacylase E2 (DBT) were downregulated in both conditions, possibly attributed to the effect of functional hDEmiRs targeting them. Our findings offer potential candidates for miRNA-directed therapeutics in these pathologies.

Our findings highlight the potential of artificial circRNAs as a novel therapeutic strategy for HCC. By harnessing their ability to act as miRNA sponges and to express immunomodulatory proteins, these engineered circRNAs offer a promising approach to overcome the challenges associated with HCC therapy.

Current therapeutic strategies prioritize isoform-specific agonists (e.g. cyclic dinucleotides like ADU-S100; non-CDNs like diABZI) and precision delivery systems, such as nanoparticles and engineered bacteria, to address challenges like short half-life and systemic toxicity...However, the pathway's dual roles, particularly its tumor-promoting effects in advanced malignancies, necessitate context-dependent modulation. This review integrates preclinical insights and clinical trial data to outline strategies for harnessing cGAS-STING signaling in cancer immunotherapy while balancing its immunostimulatory and immunosuppressive outputs.